Is cycloserine a bactericidal or bacteriostatic drug?

Cycloserine (Cycloserine) is an antibiotic mainly used to treat multidrug-resistant tuberculosis (MDR-TB). Cycloserine is a bacteriostatic drug, not a bactericidal drug. Its mechanism of action is to inhibit the growth and reproduction of Mycobacterium tuberculosis by interfering with the synthesis of bacterial cell walls.

The cell wall of bacteria is composed of peptidoglycan (peptidoglycan). The synthesis of peptidoglycan is a key process for bacterial survival and reproduction. Cycloserine interferes with the synthesis of peptidoglycan by competitively inhibiting two key enzymes, namely alanine lysine aminotransferase and D-alanine-D-alanine synthase. The role of these two enzymes is to incorporate D-alanine into the peptidoglycan precursor, forming an important component of the bacterial cell wall. By inhibiting the activity of these enzymes, cycloserine prevents the normal synthesis of peptidoglycan, causing bacteria to be unable to form a complete cell wall, thereby inhibiting their growth and reproduction.

Although cycloserine mainly works by inhibiting the growth of bacteria, under certain conditions, it may also show a certain bactericidal effect. Especially at high concentrations or when bacteria are in a rapid growth phase, cycloserine may cause severe defects in the bacterial cell wall, thereby triggering lysis and death of the bacterial cells. However, for its role as a first-line treatment, cycloserine is primarily classified as a bacteriostatic agent.

In the treatment of tuberculosis, cycloserine is often used in combination with other anti-tuberculosis drugs. The purpose of this combination therapy is to use the different mechanisms of action of multiple drugs to comprehensively attack Mycobacterium tuberculosis, prevent the development of drug resistance, and improve the overall treatment effect. Due to the increasingly serious drug resistance problem of Mycobacterium tuberculosis, cycloserine plays an important role as a second-line drug in the treatment of multidrug-resistant tuberculosis.